The finding that basophil counts may have prognostic significance aligns with a growing body of research into basophils in ...

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

The post hoc analysis of the AGAVE-201 trial found that axatilimab demonstrated consistent response rates in patients with chronic graft-vs-host disease (GVHD), regardless of the number or type of ...

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...